Ji L, Ravi S, Wright L, Nguyen V, Wiley J, Vukelic M
Arch Dermatol Res. 2024; 317(1):159.
PMID: 39739136
PMC: 11685255.
DOI: 10.1007/s00403-024-03625-6.
Kumthekar A, Ashrafi M, Deodhar A
Clin Rheumatol. 2023; 42(9):2251-2265.
PMID: 37097525
DOI: 10.1007/s10067-023-06605-9.
Wang C, Tsai H
World J Gastroenterol. 2022; 28(23):2527-2545.
PMID: 35949355
PMC: 9254143.
DOI: 10.3748/wjg.v28.i23.2527.
Patel S, Kumthekar A
Rheumatol Ther. 2021; 9(1):49-71.
PMID: 34797530
PMC: 8814223.
DOI: 10.1007/s40744-021-00397-7.
Maharaj A, Adebajo A
Clin Rheumatol. 2021; 40(9):3411-3418.
PMID: 34180027
DOI: 10.1007/s10067-021-05841-1.
Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs.
Keskin Y, Nas K, Kilic E, Sargin B, Acer Kasman S, Alkan H
Arch Rheumatol. 2021; 36(1):1-9.
PMID: 34046563
PMC: 8140874.
DOI: 10.46497/ArchRheumatol.2021.7874.
LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan.
Okada M, Kurimoto S, Ganz F, Boehncke W
PLoS One. 2021; 16(1):e0245954.
PMID: 33503031
PMC: 7840027.
DOI: 10.1371/journal.pone.0245954.
Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study.
Lubrano E, Delle Sedie A, Romanelli M, Chimenti M, Bianchi L, Piaserico S
Clin Rheumatol. 2020; 40(6):2251-2262.
PMID: 33155160
DOI: 10.1007/s10067-020-05482-w.
The Management of Erythrodermic Psoriasis Complicated by Cyclosporine.
Rao S, Bernshteyn M, Sohal R, Proumen R, Goodman A, Shepherd Z
Case Rep Dermatol Med. 2020; 2020:5215478.
PMID: 32963844
PMC: 7495151.
DOI: 10.1155/2020/5215478.
Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation.
Mathew A, Chandran V
Rheumatol Ther. 2020; 7(2):287-300.
PMID: 32323218
PMC: 7211219.
DOI: 10.1007/s40744-020-00207-6.
The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review.
Canete J, Pinto Tasende J, Rebollo Laserna F, Gomez Castro S, Queiro R
Rheumatol Ther. 2020; 7(2):237-257.
PMID: 32270447
PMC: 7211228.
DOI: 10.1007/s40744-020-00202-x.
Treatment guidelines in psoriatic arthritis.
Ogdie A, Coates L, Gladman D
Rheumatology (Oxford). 2020; 59(Suppl 1):i37-i46.
PMID: 32159790
PMC: 7065461.
DOI: 10.1093/rheumatology/kez383.
Analysis of cardiovascular risk and carotid intima-media thickness in patients with psoriasis.
Abrahao-Machado E, Mendonca J, Arruda A, Nucci L, Santos M
An Bras Dermatol. 2020; 95(2):150-157.
PMID: 32122693
PMC: 7175101.
DOI: 10.1016/j.abd.2019.07.004.
Cardiovascular Risk in Psoriasis Patients: Clinical, Functional and Morphological Parameters.
Oliveira A, Simoes M, Simoes R, Malachias M, Rezende B
Arq Bras Cardiol. 2019; 113(2):242-249.
PMID: 31340236
PMC: 6777896.
DOI: 10.5935/abc.20190123.
Management of Psoriasis and Psoriatic Arthritis in a Multidisciplinary Rheumatology/Dermatology Clinic.
Cunha J, Qureshi A, Reginato A
Fed Pract. 2019; 32(Suppl 12):14S-20S.
PMID: 30766103
PMC: 6375462.
Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
Walsh J, Adejoro O, Chastek B, Palmer J, Hur P
J Manag Care Spec Pharm. 2018; 24(7):623-631.
PMID: 29952704
PMC: 10397599.
DOI: 10.18553/jmcp.2018.24.7.623.
Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.
Singh S, Facciorusso A, Singh A, Vande Casteele N, Zarrinpar A, Prokop L
PLoS One. 2018; 13(5):e0195123.
PMID: 29771924
PMC: 5957395.
DOI: 10.1371/journal.pone.0195123.
Addressing comorbidities in psoriatic disease.
Patel P, Rosen C, Chandran V, Ye Y, Gladman D
Rheumatol Int. 2017; 38(2):219-227.
PMID: 29185085
DOI: 10.1007/s00296-017-3895-y.
Psoriasis comorbidities: complications and benefits of immunobiological treatment.
de Carvalho A, Romiti R, Souza C, Paschoal R, Milman L, Meneghello L
An Bras Dermatol. 2017; 91(6):781-789.
PMID: 28099601
PMC: 5193190.
DOI: 10.1590/abd1806-4841.20165080.
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.
Gossec L, Coates L, de Wit M, Kavanaugh A, Ramiro S, Mease P
Nat Rev Rheumatol. 2016; 12(12):743-750.
PMID: 27829672
DOI: 10.1038/nrrheum.2016.183.